
89bio, Inc.
ETNB
Updated: 22/09/2026, 09:32:31
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.
No summaries found.
- Share price
- $14.84
- Market cap
- $2.20B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Rohan Palekar
- Employees
- 93
- IPO date
- 11/11/2019
- Beta
- 1.263
- Last dividend
- $0.00
- Day range
- $14.84 – $14.84
- 52-week range
- $4.16 – $15.06
- 1-day performance
- 0.00%
- 1-year performance
- 256.73%
- Current drawdown (1Y)
- -1.46%
- CIK
- 0001785173
- CUSIP
- 282559103
- ISIN
- US2825591033
- Created
- 07/12/2025, 03:51:13
- Last update
- 22/09/2026, 09:32:31
Track 89bio, Inc. with an AI analyst
See which prediction-market events move ETNB, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.